Clément Picard

Clément Picard

Auto-generated profile, based on publicly available information

Clément Picard

Pneumology Department, Lung transplant Program, Foch Hospital, Suresnes, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
ABAlexandre Brudon
Alexandre Brudon
MLMarie Legendre
Marie Legendre
AMArthur Mageau
Arthur Mageau
JBJulien Bermudez
Julien Bermudez
PBPhilippe Bonniaud
Philippe Bonniaud
TNthe OrphaLung network
the OrphaLung network
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.

12 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ARAntoine Roux
Antoine Roux
VBVincent Bunel
Vincent Bunel
NBNatalia Belousova
Natalia Belousova
JMJonathan Messika
Jonathan Messika
STSébastien Tanaka
Sébastien Tanaka
FPFrancois Parquin
Francois Parquin
Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an IgG-degrading enzyme derived from Streptococcus pyogenes, is a novel agent that has been used to convert positive crossmatches to negative in kidney transplant candidates, allowing transplantation to occur. We present the first case of imlifidase use for antibody depletion in a highly sensitized lung transplant candidate who went on to undergo a successful bilateral lung transplant.

1 May 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EFEric Farfour
Eric Farfour
CPClément Picard
Clément Picard
LBLaurence Beaumont
Laurence Beaumont
PLPhilippe Lesprit
Philippe Lesprit
MBMarie-Christine Ballester
Marie-Christine Ballester
Marc VasseMarc Vasse
Marc Vasse

21 June 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
HCH. Clermidy
H. Clermidy
OMOlaf Mercier
Olaf Mercier
GBG. Brioude
G. Brioude
PMP. Mordant
P. Mordant
GFG. Fadel
G. Fadel
FTF. Tronc
F. Tronc
Pleuroparenchymal fibroelastosis (PPFE) has no currently available specific treatment. Benefits of lung transplantation (LT) for PPFE are poorly documented. We conducted a nation-wide multicentric retrospective study in patients who underwent lung or heart-lung transplantation for chronic end-stage lung disease secondary to PPFE between 2012 and 2022 in France. Thirty-one patients were included. At transplantation, median age was 48 years [IQR 35 - 55]. 64.5% were women. Twenty-one (67.7%) had idiopathic PFFE. Sixteen (52%) had bilateral LT, 10 (32%) had single LT, 4 (13%) had lobar transplantation and one (3%) had heart-lung transplantation. Operative mortality was 3.2%. Early mortality (< 90 days or during the first hospitalization) was 32%. Eleven patients (35.5%) underwent reoperation for hemostasis. Eight (30.8%) experienced bronchial complications. Mechanical ventilation time was 10 days [IQR 2-55]. Length of stay in intensive care unit and hospital were 34 [IQR 18-73] and 64 [IQR 36-103] days, respectively. Median survival was 21 months. Post-transplant survival rates after 1, 2, and 5 years were 57.9%, 42.6% and 38.3% respectively. Low albuminemia (p=0.046), FVC (p=0.021), FEV1 (p=0.009) and high emergency lung transplantation (p=0.04) were associated with increased early mortality. Oversized graft tended to be correlated to a higher mortality (p=0.07). LT for PPFE is associated with high post-operative morbi-mortality rates. Patients requiring high emergency lung transplantation with advanced disease, malnutrition, or critical clinical status experienced worse outcomes. NCT05044390.

23 August 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
NBNatalia Belousova
Natalia Belousova
EHElla Huszti
Ella Huszti
QLQixuan Li
Qixuan Li
AVAnastasiia Vasileva
Anastasiia Vasileva
RGRasheed Ghany
Rasheed Ghany
TMTereza Martinu
Tereza Martinu
The Acute Rejection Score (A-score) in lung transplant recipients, calculated as the average of acute cellular rejection A-grades across transbronchial biopsies, summarises the cumulative burden of rejection over time. We assessed the association between A-score and transplant outcomes in two geographically distinct cohorts. The primary cohort included 772 double lung transplant recipients. The analysis was repeated in 300 patients from an independent comparison cohort. Time-dependent multivariable Cox models were constructed to evaluate the association between A-score and CLAD or graft failure. Landmark analyses were performed with A-score calculated at 6 and 12 months post-transplant. In the primary cohort, no association was found between A-score and graft outcome. However, in the comparison cohort, time A-score was associated with CLAD both as a time-dependent variable (HR 1.51, p < 0.01), and when calculated at 6 and 12 months post-transplant. The A-score can be a useful predictor of lung transplant outcomes in some settings but is not generalizable across all centres; its utility as a prognostication tool is therefore limited.

2 July 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MRMarc Raynaud
Marc Raynaud
NBNatalia Belousova
Natalia Belousova
MGMatthieu Glorion
Matthieu Glorion
CHCaroline Hillebrand
Caroline Hillebrand
CPClément Picard
Clément Picard
ARAntoine Roux
Antoine Roux